Phillips-Medisize Wins Contract to Manufacture First Electronic-Enabled Combination Drug Delivery Product
22.10.2019 18:30:00 EEST | Business Wire | Press release
Phillips-Medisize, a Molex company, announced today an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable combination product – which is replaced every two days – is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize. Several state-of-the-art Phillips-Medisize facilities are involved in various stages of manufacturing the combination product – including molding, assembly, drug handling, labeling, reconciliation and more.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and President, Phillips-Medisize.
Pending receipt of FDA approval, Phillips-Medisize is contracted to provide commercialization services from its Hudson, WI-based manufacturing site. The combination product is slated for launch in 2H 2020. Backed by Phillips-Medisize’s scalability to move to high volume production, the product will be well positioned for a successful market launch.
Strong potential also exists to bring the device onto a connected health platform in the future, by embedding low-cost connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
About Phillips-Medisize
Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005826/en/
Contact information
For more information, contact:
Heather Ditzler
Phone +1 715-377-7261
heather.ditzler@phillipsmedisize.com
Paula Kasper (Europe)
Phone +41448383933
paula.kasper@phillipsmedisize.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdantis Rebrands as the AI Super-Agent for MRO, Sets Sights on AI-Native Enterprise Asset Management8.9.2026 17:06:00 EEST | Press release
Verdantis, the AI company for spare parts and MRO inventory optimization in asset-intensive industries, today unveiled its new brand identity as the AI Super-agent for MRO and announced it is building toward a fully AI-native Enterprise Asset Management (EAM) platform. Verdantis’s super-agent orchestrates nine specialized AI agents across the decisions that decide plant uptime: spare parts, criticality, demand, reorder, and work order planning. These decisions set working capital, maintenance spend, and whether a critical asset runs and, in most plants, they are still made in spreadsheets and disconnected systems. The positioning is for the teams who own uptime - maintenance, reliability, and MRO supply chain leaders in oil and gas, mining, utilities, chemicals, and manufacturing. And it reflects an AI-first architecture: agents decide and act by default; people supervise, override, and teach the system. Every human override creates feedback that helps the system learn. That principle
HyperLight Welcomes VentureTech Alliance to Series C, Deepening TFLN Integration Across the Semiconductor Ecosystem8.9.2026 17:00:00 EEST | Press release
HyperLight Corporation ("HyperLight"), a leader in thin-film lithium niobate (TFLN) photonics, today announced that VentureTech Alliance ("VTA") has joined its Series C financing round. VTA is a venture investment firm focused on the semiconductor industry, with a portfolio built across the semiconductor technology stack — including circuit design, foundry-adjacent process technology, EDA, advanced packaging, and photonics. VTA's participation extends the ecosystem alignment that defined the round, which brought together investors spanning silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure capital. With VTA's addition, the syndicate now reaches further into the semiconductor manufacturing and design-enablement layers on which high-volume photonics production depends. "The transition to TFLN is not a component decision — it is an ecosystem decision," said Mian Zhang, CEO of HyperLight. "Getting TFLN into volume requires the proc
EcoOnline Appoints Conor O’Loughlin as CEO8.9.2026 17:00:00 EEST | Press release
EcoOnline, a global provider of software that transforms how organisations protect people and the planet, today announced the appointment of Conor O’Loughlin as Chief Executive Officer, effective immediately. O’Loughlin succeeds Tom Goodmanson and will lead the Company into its next chapter of growth and innovation, continuing EcoOnline’s mission of keeping employees safe across the globe and supporting more than 11,000 customers. O’Loughlin is an experienced, growth-oriented technology operator and founder. He co-founded fitness technology company Glofox, scaling it into a global SaaS business serving customers in more than 80 countries before its acquisition by ABC Fitness in 2022. Following the acquisition, he served as Platform President and later Global Chief Revenue Officer at ABC Fitness, leading strategy across the company’s revenue-generating activities. “Keeping people safe at work is more important than ever, and EcoOnline does it with a depth of expertise that few can match
Hawker Operators Gain Access to High-Speed Starlink Connectivity Through Textron Aviation Customer Support Network8.9.2026 17:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Starlink’s high-speed internet is now available for the Hawker 700, 800 and 900 series aircraft, following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC). The STC includes the Starlink Aviation Performance Kit, which utilizes Starlink’s advanced constellation of Low Earth Orbit (LEO) satellites to help customers stay connected throughout their journey with more reliability over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908170569/en/ Hawker operators gain access to high-speed Starlink connectivity through Textron Aviation Customer Support network “Hawker operators continue to look to Textron Aviation for long-term care and upgrade solutions that ensure their aircraft remain mission-ready in today’s operat
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study8.9.2026 16:47:00 EEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study. The study is designed to evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee. Dr. Juan Osorio and Dr. Emilio Tufiño, who both specialize in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. “I am pleased to be the Principal Investigator for this important study, and we are excited to be the first to initiate clinical study enrollment. The team here in Panamá looks forward to contributing the data that will support a larger clinical study and subsequent market entry,” stated Dr. Osorio. “The speed at which Dr. Osorio and the clinical team were able to identify, enroll, and treat the first patient underscores the significant unmet clini
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom